A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy
E. J. Pomeroy, J. T. Hunzeker, M. T. Kluesner, M. R. Crosby, W. S. Lahr, L. Bendzick, J. S. Miller, B. R. Webber, M. A. Geller, B. Walcheck, M. Felices, T. K. Starr, B. S. Moriarity
This paper develops a CRISPR/Cas9-based method to edit human NK cells, enhancing their anti-cancer activity by knocking out ADAM17 and PD1.
bioRxiv · Sep 29, 2018Immunology